版本:
中国

BRIEF-Novartis says BAF312 filing planned for H1 2018 in relapsing MS

May 31 Novartis Ag

* Says 2017 u.s. Launch of ms drug glatopa 40 mg still possible, but unlikely after facility problems

* Says on track to launch five major biosimilars between now and 2020

* Says has 40 potential filings in us and eu 2017-2020

* Says cantos study of acz885 drug for cardiovascular disease has reached the defined number of events, on track for mid-2017 readout

* Says baf312 filing planned in us h1 2018 in relapsing ms, labeling of population studied a review issue Source text for Eikon: Further company coverage: (Reporting by John Miller)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐